Pharmaceutical companies face a paradox: They exist to improve human health, yet their manufacturing processes have a pronounced negative environmental impact. A landmark 2019 study in the Journal of Cleaner Production caught the attention of regulators, investors, and the industry itself with a finding that pharma’s emission intensity was 55% higher than that of the automotive industry. Today, environmental sustainability has moved from being a background concern to being a core operational and managerial priority.

This article reviews what sustainability means for the pharmaceutical sector, why it matters, and how companies are responding.

What Is Sustainability in the Pharmaceutical Industry?

Sustainability in the pharmaceutical industry refers to practices that curb environmental impact throughout the entire product lifecycle, from raw material sourcing and active pharmaceutical ingredient (API) manufacturing through packaging, distribution, and end-of-life disposal. It encompasses efforts to cut greenhouse gas emissions, minimize waste, conserve water, and prevent pharmaceutical contamination of natural ecosystems.

Pharma sustainability intersects with strict regulatory requirements for product quality and safety. Changes to manufacturing processes have to satisfy complex validation procedures, which means eco-friendly practices usually must be designed into new products, rather than retrofitted into existing ones. Consequently, ecological improvement tends to move more slowly than in other industries.

Key Takeaways

  • Pharma sustainability has shifted from a voluntary practice to mandatory one, with the European Union leading through disclosure rules and “polluter pays” requirements.
  • Most pharma emissions come from the supply chain, not the factory floor.
  • Sustainability has become a factor in procurement decisions; leading pharma companies now evaluate suppliers on environmental performance alongside quality, cost, and reliability.
  • Sustainability and cost reduction often go hand in hand: less waste, lower energy use, smaller bills.

Sustainability in the Pharmaceutical Industry Explained

The push toward sustainability in pharma reflects several converging forces, with regulation foremost—and the European Union leading the charge. The European Green Deal—the EU’s overarching strategy for reaching climate neutrality by 2050—has spawned a dense web of rules that directly affects pharmaceutical manufacturing. Among them, the Corporate Sustainability Reporting Directive (CSRD) requires large companies to report environmental impacts under standardized frameworks. EU pharmaceutical legislation has strengthened to the point that European regulators can now refuse market authorization for a drug if its environmental risk assessment reveals harm that the company can’t adequately mitigate.

The US picture is more fragmented. There’s no federal counterpart to the EU’s CSRD, and momentum on national climate disclosure has stalled. Instead, requirements are emerging at the state level—California’s SB 253, for instance, will require large companies to report greenhouse gas emissions. Meanwhile, the EPA continues to regulate pharmaceutical waste under existing hazardous-waste rules. For manufacturers operating on both sides of the Atlantic, that means EU standards often set the effective baseline, even for US operations.

Beyond compliance, there’s a financial dimension to sustainability as investors increasingly scrutinize environmental, social, and governance (ESG) performance. European asset managers, in particular, frequently vote in favor of shareholder proposals that push companies toward stronger ESG action. Sustainability-linked financing instruments—where loan terms are tied to meeting carbon or access targets—have also entered the pharma sector.

And there’s an unavoidable operational reality: Pharmaceutical manufacturing is resource-intensive. Chemical synthesis requires large volumes of water and energy; solvents dominate process waste. As a result, drug production can generate 50 to 100 tons of waste for every ton of finished product. Global cold-chain distribution—the refrigerated trucks, air freight, and temperature-controlled warehouses required for biologic drugs and vaccines—adds substantial transport emissions and packaging waste. These aren’t abstract concerns—they show up in operating costs and, increasingly, in regulatory exposure. The good news is that companies that reduce energy and waste also tend to lower their expenses.

Why Is Environmental Sustainability Important in the Pharmaceutical Industry?

The case for sustainability in pharma spans regulatory, environmental, financial, operational, and reputational dimensions:

  • Regulatory requirements: As described above, the pharma regulatory landscape has shifted from voluntary commitments to binding obligations. Yet another example is the EU’s revised Urban Wastewater Treatment Directive, adopted in November 2024, which requires pharmaceutical producers to cover at least 80% of the costs of removing micropollutants from urban wastewater. This represents the first time the “polluter pays” principle has been applied to medicines at scale.
  • Environmental benefits: Pharmaceutical manufacturing carries measurable environmental consequences—carbon emissions, water consumption, waste generation, and the release of APIs into natural ecosystems. Reducing this pollution benefits public health, biodiversity, and climate equilibrium.
  • Improved cost savings: Sustainability initiatives often pay for themselves. McKinsey estimates that 30% of pharmaceutical emissions can be abated in ways that generate cost savings, and that another 15% can be eliminated at no net cost. Better still, the savings from the profitable measures can fund more expensive ones—so, on a combined basis, companies can reach 60% to 70% total abatement without any net cost, according to McKinsey. Solvent recovery, renewable energy procurement, process efficiency, and waste reduction all cut down on input costs.
  • Improved trust: Patients, medical systems, and partners increasingly factor environmental performance into their decisions. The UK’s National Health Service—the first health system to commit to net zero—now embeds environmental criteria in its procurement process. And because medicines account for roughly one-quarter of the NHS’s carbon emissions, pharmaceutical suppliers face particular scrutiny. Demonstrating environmental accountability strengthens credibility with patients, providers, and partners alike.
  • Supply chain resilience: Sustainability and supply chain resilience are complementary. Localizing production minimizes transport emissions and exposure to disruption. Diversifying suppliers can improve both environmental performance and security of supply.

The Environmental Consequences of the Pharmaceutical Industry

Without sustainable practices, the environmental consequences originating from the pharmaceutical sector are hard to ignore. Pharmaceutical manufacturing consumes significant energy and water, generates considerable waste, and releases active compounds into ecosystems where they affect aquatic life and may accelerate antimicrobial resistance. Even its products’ packaging and distribution carry environmental costs. Consequences include:

  • Energy costs: Pharma’s carbon footprint from direct drug manufacturing is large, but it’s only the obvious portion. McKinsey estimates that half of pharmaceutical emissions originate upstream—in raw material extraction, API synthesis, and other supplier operations. That means the environmental consequences of the industry’s energy appetite extend far beyond any single company’s factory walls.
  • Packaging waste: Blister packs, bottles, cartons, and cold-chain insulation all generate waste, contributing materially to the industry’s environmental footprint. Because blister packs consist of plastic-aluminum composite materials, they’re incompatible with standard recycling, so most end up in landfills or are incinerated.
  • Medical waste: Expired medications, single-use injection devices, and contaminated packaging all require specialized disposal—typically, incineration. Better demand forecasting and tighter perishable inventory management can reduce the volume of pharmaceutical products that wind up in healthcare waste streams.
  • Environmental contamination: Pharmaceuticals enter the environment through multiple pathways. Patient excretion accounts for the largest share of pharmaceutical residues in water systems, followed by improper disposal. Manufacturing discharge, though a smaller percentage globally, can generate acute local hotspots.
  • Trace contamination: Even at low concentrations, drug compounds in water systems cause ecological and public health risks. Active ingredients designed to produce biological effects in humans can affect aquatic organisms. Antimicrobial resistance is an emerging concern; contaminated discharge from antibiotic manufacturing has been linked to the development of resistant bacteria.

7 Strategies to Improve Sustainability in the Pharmaceutical Sector

Strategies to reduce pharmaceutical companies’ environmental impact include operational, technological, and organizational approaches, and they address the challenges of natural resource use, waste, chemical safety, and emissions. For emissions alone, companies track three categories: Scope 1 covers direct emissions from owned sources, such as onsite fuel combustion and vehicle fleets; Scope 2 covers indirect emissions from energy purchases, such as electricity and oil; and Scope 3 covers everything else in the value chain (suppliers, raw materials, logistics, product end-of-life). The following strategies tackle the various environmental challenges and all three carbon-emission scopes.

  1. Sustainable Manufacturing and Waste Reduction

    Manufacturing efficiency is considered the foundation of pharmaceutical sustainability. Continuous manufacturing—where production flows without the batch-to-batch interruptions of traditional processes—offers lower energy consumption, reduced waste, and a smaller facility footprint compared to conventional methods. The US Food and Drug Administration has actively supported the adoption of continuous manufacturing, noting that it can shorten production times and improve manufacturing efficiency. Separately, solvents represent the largest category of process waste in pharmaceutical manufacturing. Recovering and recycling solvents cuts disposal costs and minimizes the need for virgin materials. AI is beginning to sharpen both approaches. For example, machine-learning models can monitor continuous manufacturing in real time to predict quality deviations before they occur, limiting defective batches, and it can fine-tune solvent-recovery processes to lift recyclable yield. But although these changes can reduce manufacturing waste, they also call for careful implementation to avoid impairing product quality or running afoul of regulatory compliance.

  2. Sustainable Packaging

    Pharmaceutical packaging sustainability presents a particular challenge: Materials must protect drug stability, meet regulatory requirements, and accommodate complex supply chains, all while curbing environmental impact. The industry is responding with several innovations. Mono-material recyclable blister packs made from polyethylene terephthalate or polypropylene are replacing hard-to-recycle plastic-aluminum composites. Paper-based alternatives are entering the market for certain applications. Glass manufacturers are developing lower-carbon production methods using electrified melting and renewable energy. A key constraint is shelf life—sustainable packaging solutions must work within the stability requirements that determine how long a drug is safe and effective. Biodegradable or recycled materials sometimes offer inferior moisture and oxygen barrier properties, which shorten medications’ shelf lives. The EU Packaging and Packaging Waste Regulation recognizes this tension by providing an exemption for pharmaceutical packaging until January 1, 2035.

  3. Safer Chemistry

    Green chemistry—that is, designing processes to decrease hazardous inputs and waste—is still guided by the 12 principles established in 1998 by two pioneering green chemists. The pharmaceutical industry has operationalized these principles through tools like Process Mass Intensity metrics and solvent selection guides developed by the American Chemical Society’s Green Chemistry Institute Pharmaceutical Roundtable. Biocatalysis—the use of enzymes in lieu of traditional chemical catalysts—has gained traction because enzymes operate under milder conditions and produce fewer byproducts than traditional metal catalysts. AI is accelerating this work, too. Machine-learning models can screen candidate reactions and greener solvents computationally before any are put into production, and they can help engineer enzymes for new biocatalytic routes—shrinking the time and material waste of trial-and-error chemistry. The EU’s revised Environmental Risk Assessment guideline is likely to accelerate adoption of safer chemistry by making environmental performance a regulatory prerequisite.

  4. Supply Chain Transparency

    For most pharmaceutical companies, supply chain emissions dwarf those produced by direct operations. One global pharmaceutical firm reports that Scope 3 emissions represent 97% of its total carbon footprint. The pattern holds industrywide. Addressing this requires visibility into supplier environmental performance and traceability back to the origins of raw materials—a monitoring burden that AI is increasingly suited to carry. Supplier-monitoring agents can continuously track performance and risk indicators within many data sources, often uncovering an emissions red flag or a lapsed target the moment it appears. Such capabilities are allowing leading pharmaceutical companies to set explicit targets—the global firm mentioned above, for example, said it aims for 95% of its spending with key suppliers to go to companies that have science-based emission targets.

    Beyond emissions, supply chain transparency helps identify risks, including water pollution from API manufacturing, hazardous waste handling at supplier sites, unsustainable raw material sourcing, and human rights violations. Companies can address these issues through the Pharmaceutical Supply Chain Initiative’s framework, which addresses five areas: ethics, human rights, health and safety, environment, and governance.

  5. Renewable Energy Upgrades

    Switching to renewable electricity to power direct operations is one of the most straightforward Scope 2 decarbonization moves for any pharmaceutical company. Most major global firms have joined RE100, the global initiative led by The Climate Group that commits members to 100% renewable electricity. Virtual power purchase agreements let companies fund offsite renewable projects and claim the green energy credits—a way to go renewable without onsite solar panels or wind turbines. Several leading pharmaceutical manufacturers have already achieved 100% renewable electricity for their global operations. But the challenge reaches beyond a company’s own operations. Major pharma companies also sponsor programs that help their suppliers go green. Energize, for example, lets pharma suppliers pool their buying power to secure renewable energy deals many couldn’t access on their own. When those suppliers switch to renewables, the pharma companies’ Scope 3 emissions shrink in turn.

  6. Circular Economy Systems

    Circular economy approaches keep materials in use instead of disposing of them. In pharmaceutical manufacturing, solvent recovery—capturing used solvents from production processes, purifying them through distillation, and returning them to the manufacturing line—is the highest-impact application. Take-back programs for inhalers, packaging, and devices are emerging, but contamination threats and regulatory complexity limit their scale. The pharmaceutical sector’s strict quality requirements make circular models harder to implement than in other industries because recycled materials may not meet the specifications required for direct contact with drug products.

  7. Improved Software and Integrated Technology

    Technology promotes sustainability in two ways: by providing the data needed to identify and track environmental impact, and by improving operations to lessen that impact. Improved inventory management systems help curtail waste from expired products and overproduction. Digital twins—virtual replicas of manufacturing processes—allow companies to simulate changes and identify efficiency opportunities before they commit any capital. AI extends this. Machine-learning forecasts ingest thousands of variables to predict demand more precisely and to shrink safety stock, while a newer generation of AI supply chain agents monitor operations continuously to identify anomalies that signal waste, optimize transport routes in line with fuel and congestion data, and alert procurement before a disruption cascades. Better forecasting and faster response mean less overproduction, fewer expedited shipments, and lower carrying costs. The result: less waste, lower emissions, and stronger financial performance.

Foster Your Sustainability Pharmaceutical Strategy With NetSuite ERP

Pharmaceutical companies implementing sustainability strategies face a consistent challenge: getting accurate, timely data from all operations, suppliers, and products. Without visibility into energy consumption, material use, waste generation, and supplier performance, even well-intentioned sustainability programs struggle to present demonstrable results or identify the highest-impact opportunities. NetSuite’s Pharmaceutical ERP for Manufacturing provides an integrated data foundation for pharmaceutical companies. Real-time dashboards consolidate data from manufacturing, inventory, procurement, and finance, making it possible to track sustainability metrics alongside those that track operations and financials.

Because that data lives in one unified platform, NetSuite’s built-in AI can act on it. AI-powered anomaly detection reveals the waste, overproduction, and process exceptions that increase emissions and cost, as AI agents monitor inventory and supplier signals continuously and recommend or take action within the limits you set. For companies managing the regulatory and operational obligations of sustainability, a single source of accurate data—and AI that puts it to work—isn’t a luxury, it’s a requirement.

Sustainability in the pharmaceutical industry has evolved from being a voluntary aspiration to become a regulated necessity. The EU’s application of “polluter pays” principles to micropollutant removal, strengthened environmental risk assessments, and expanding disclosure requirements are reshaping how companies approach manufacturing, sourcing, and reporting. At the same time, the economics of sustainability are more favorable than many assume. The winners in this transition will be the companies that treat sustainability not as a compliance burden but as an operational discipline—one that cuts costs, strengthens supply chains, and positions the business for the regulatory and market expectations ahead.

Sustainability in the Pharmaceutical Industry FAQs

What are the core sustainability practices in the pharmaceutical industry?

Core sustainability practices include decreasing greenhouse gas emissions through renewable energy and process efficiency, minimizing manufacturing waste through solvent recovery and continuous manufacturing, adopting green chemistry principles in product development, implementing sustainable packaging, and urging suppliers to improve their environmental performance.

What are the key pillars of sustainable pharmacy?

Sustainable pharmacy rests on environmental stewardship throughout the product lifecycle. This includes responsible manufacturing that minimizes energy, water, and waste; supply chain transparency and traceability; sustainable packaging design; proper disposal pathways for unused medications; and measuring and reporting environmental impact against science-based targets.